The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1496090
This article is part of the Research Topic Prognostic Biomarkers and Gene Signatures in Endometrial, Ovarian, and Cervical Cancer View all 3 articles
Col1A1 As a New Decoder Of Clinical Features And Immune Microenvironment In Ovarian Cancer
Provisionally accepted
Xiao XIAO
1
Fangyi Long
2*
Shaolan Yu
2*
Wengjuan Wu
1*
Dayan Nie
2*
Xiaoyan Ren
3
Wen Li
3*
Xujuan Wang
3*
Ling Yu
2*
Pinghan Wang
2*
Gang Wang
1*- 1 Department of Gynecology, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
- 2 Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
- 3 Chengdu Medical College, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Backgrounds: Collagen type I alpha 1 chain (COL1A1) is a key protein encoding fibrillar collagen, playing a crucial role in the tumor microenvironment (TME) due to its complex functions and close association with tumor invasiveness. This has made COL1A1 a focal point in cancer biology research.However, studies investigating the relationship between COL1A1 expression levels and clinical characteristics of ovarian cancer (OC) remain limited.Methods: This study integrated resources from publicly available online databases and immunohistochemistry (IHC) techniques to analyze and validate COL1A1 expression in OC tissues, and evaluated its potential association with clinical features in OC patients. The prognostic value of COL1A1 was assessed using Kaplan-Meier (KM) survival curve analysis. The TIMER and TISIDB databases to explore the potential relationship between COL1A1 expression and immune microenvironment in OC tissues. The LinkedOmics and INPUT2 databases were used to analyze differential gene expression in OC, This was followed by enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) annotations to identify and predict potential signaling pathways associated with COL1A1.Results: Our study demonstrated that COL1A1 expression was significantly elevated in OC tissues compared to normal ovarian tissues. This elevated expression was closely associated with tumor metastasis, poor prognosis, and advanced pathological stages in OC patients. Moreover, COL1A1 expression showed a significant correlation with immune cell infiltration and the expression of immune-related genes within the TME.Further analyses revealed that COL1A1 and its co-expressed genes were primarily enriched in key signaling pathways involved in OC invasion, metastasis, and angiogenesis, indicating its potential role in driving OC progression.Conclusions: Our study found that upregulation of COL1A1 expression is significantly associated with lymph node metastasis of OC and can affect the immune microenvironment. Based on this, COL1A1 could serve as a promising biomarker for OC prognosis and provide a new perspective for the development of potential immunotherapies for patients with OC.
Keywords: col1a11, ovarian cancer (OC)2, Immune infiltration3, Biomarker4, Prognosis5, Tumor microenvironment6
Received: 16 Sep 2024; Accepted: 12 Dec 2024.
Copyright: © 2024 XIAO, Long, Yu, Wu, Nie, Ren, Li, Wang, Yu, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Fangyi Long, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Shaolan Yu, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Wengjuan Wu, Department of Gynecology, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Dayan Nie, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Wen Li, Chengdu Medical College, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Xujuan Wang, Chengdu Medical College, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Ling Yu, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Pinghan Wang, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Gang Wang, Department of Gynecology, Sichuan Provincial Hospital for Women and Children, The Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.